Berlin Heals Announces Publication of Two-Year Clinical Outcomes of Cardiac Microcurrent Therapy in ESC Heart Failure USA
ZUG, Switzerland, July 16, 2025 /CNW/ -- Berlin Heals, a pioneer in bioelectric medicine for the treatment of heart failure, is pleased to announce the publication of a new peer-reviewed study titled "Two-year outcomes of a cardiac microcurrent device in chronic heart failure: A first-in-human pilot study" in the ESC Heart Failure journal.
The study presents the long-term follow-up of patients enrolled in the initial pilot trial of the Cardiac Microcurrent Implantable Device (C-MIC), designed to restore myocardial function in patients with chronic heart failure. This publication marks the first report of sustained clinical benefit following the discontinuation of active therapy—two years after initial device implantation.
Study Summary
The two-year follow-up evaluated the safety, durability, and efficacy of C-MIC therapy in seven patients with chronic heart failure (NYHA Class III, mean LVEF 31.7%). Patients who had completed the initial six-month pilot trial were reassessed for mortality, hospitalization rates, device-related adverse events, and functional status.
Key findings include:
No device-related adverse events were reported over the two-year period.
LVEF improvements of +11.6% at 6 months were sustained at +12.6% two years after deactivation of the device.
6-minute walk distance (6MWD) improved by over 200 meters at 6 months and remained nearly +191 meters above baseline at two years.
Improvements in NYHA functional class and SF-36 quality-of-life scores were maintained.
Only one patient required C-MIC reactivation.
"These findings offer important clinical insights into the long-term potential of C-MIC therapy," said Prof. Dragana Kosevic, the study's first author and Co-Principal Investigator. "What's most encouraging is that the improvements in cardiac function and patient well-being were sustained even after the device was deactivated, suggesting a disease-modifying effect."
John Brumfield, CEO of Berlin Heals, added: "The publication of this study reinforces our confidence in microcurrent therapy as a transformative treatment for heart failure. These two-year results validate both the safety and long-lasting impact of C-MIC and set the stage for larger clinical trials."
Berlin Heals is currently expanding its clinical development program, with the multicenter C-MIC III trial now underway in several European countries.
To access the full publication in ESC Heart Failure, please visit http://doi.org/10.1002/ehf2.15369.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
11 hours ago
- Cision Canada
Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis
- Approximately 3,800 people in Canada are now eligible for ALYFTREK, with up to 60 people potentially eligible for a medicine that treats the underlying cause of their disease for the first time - TORONTO, July 22, 2025 /CNW/ - Vertex Pharmaceuticals today announced that Health Canada has granted Marketing Authorization for Pr ALYFTREK TM (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for patients living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. ALYFTREK brings a potentially transformative therapy to up to 60 people living with CF in Canada who were not previously eligible for a CFTR modulator. As the first once-daily CFTR modulator, ALYFTREK may also provide a new treatment option and flexibility for approximately 3,800 people given the need to take CFTR modulators with fat-containing food. "ALYFTREK represents the next generation of CFTR modulator treatment and is a testament to our long-standing goal to address the underlying cause of cystic fibrosis, treat more people living with CF, and bring more people to normal levels of CFTR function," said Michael Siauw, General Manager at Vertex Pharmaceuticals (Canada) Incorporated. "With once-daily dosing, eligibility in 113 additional mutations, and the potential to lower sweat chloride levels even further, ALYFTREK brings us one step closer to achieving this goal." This approval is based on a comprehensive Phase 3 pivotal program, including more than 1,000 patients across more than 20 countries and more than 200 sites. The Phase 3 studies in people with CF ages 12 years and older met their primary endpoint (non-inferiority on absolute change from baseline in ppFEV 1 compared to TRIKAFTA) and all key secondary endpoints (including absolute change from baseline in sweat chloride [SwCl] compared to TRIKAFTA). In the Phase 3 study of children with CF ages 6-11 years, ALYFTREK demonstrated safety, the primary endpoint. Secondary endpoints, such as absolute change from baseline in ppFEV 1 and absolute change from baseline in SwCl, demonstrate the benefit of ALYFTREK in this age group. ALYFTREK was generally well tolerated across all studies. "For Canadian patients and families, the approval of ALYFTREK represents significant progress towards improved care," said Dr. Bradley Quon, Medical and Research Director of the Adult Cystic Fibrosis Program at St. Paul's Hospital, and Associate Professor of Medicine in the Faculty of Medicine at the University of British Columbia. "Lower levels of sweat chloride combined with the convenience of a once-a-day treatment provides a new option that has the potential to both improve CFTR function and reduce treatment burden." ALYFTREK is currently approved in the U.S., UK and European Union and is under regulatory review in Switzerland, Australia and New Zealand. About Cystic Fibrosis Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 109,000 people, including 94,000 people in North America, Europe and Australia. CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF, and these mutations can be identified by a genetic test. While there are many different types of CFTR mutations that can cause the disease, the vast majority of people with CF have at least one F508del mutation. CFTR mutations lead to CF by causing CFTR protein to be defective or by leading to a shortage or absence of CFTR protein at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung damage that eventually leads to death for many patients. The median age of death is in the 30s, but with treatment, projected survival is improving. Today Vertex CF medicines are treating over 75,000 people with CF in more than 60 countries on six continents. This represents 2/3 of the diagnosed people with CF eligible for CFTR modulator therapy. Sweat chloride, which measures CFTR function, is used to diagnose CF. The diagnostic threshold for CF is SwCl ≥60 mmol/L, while levels between 30-59 indicate CF is possible and more testing may be needed to make the diagnosis of CF. A SwCl level of <30 mmol/L is seen in people who carry one copy of a CFTR gene mutation but do not have any manifestation of disease (carriers). At a population level, higher levels of SwCl are associated with more severe disease. Restoring CFTR function leads to lower levels of SwCl. Restoring SwCl levels below 30 mmol/L has long been the ultimate treatment goal for Vertex, as levels below 30 mmol/L are considered normal and are typical of CF carriers who do not have disease. About ALYFTREK TM (vanzacaftor/tezacaftor/deutivacaftor) In people with CF, mutations in the CFTR gene lead to decreased quantity and/or function of the CFTR protein channel at the cell surface. Vanzacaftor and tezacaftor are designed to increase the amount of CFTR protein at the cell surface by facilitating the processing and trafficking of the CFTR protein. Deutivacaftor is a potentiator designed to increase the channel open probability of the CFTR protein delivered to the cell surface to improve the flow of salt and water across the cell membrane. ALYFTREK is approved in the U.S., UK, and Canada for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene. ALYFTREK is approved in the European Union for the treatment of CF in patients ages 6 years and older who have at least one non-class I mutation in the CFTR gene. Boxed Warning Elevated transaminases have been observed in some patients treated with ALYFTREK. Cases of liver failure leading to transplantation and death have been reported in patients with and without a history of liver disease taking a fixed dose combination drug containing elexacaftor, tezacaftor, and ivacaftor, which contains one same (tezacaftor) and one similar (ivacaftor) active ingredient as ALYFTREK. Liver injury has primarily been reported within the first 6 months following initiation of elexacaftor/tezacaftor/ivacaftor. See full ALYFTREK Product Monograph for further details. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements by Michael Siauw and Dr. Bradley Quon, and statements regarding the anticipated eligible patient population in Canada and expectations for the ALYFTREK regulatory submissions in Switzerland, Australia and New Zealand. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy, or other reasons, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Vertex Pharmaceuticals Incorporated Investors: [email protected] Media: [email protected] or Canada: +1 647-790-1600 SOURCE Vertex Pharmaceuticals (Canada) Inc.
Cision Canada
13 hours ago
- Cision Canada
The 2025 International Congress of Basic Science Opens in Beijing
BEIJING, July 22, 2025 /CNW/ -- The 2025 International Congress of Basic Science (ICBS) officially kicked off on July 13 at the China National Convention Center in Beijing, gathering the world's brightest scientific minds for a landmark two-week conference. The event brings together four Fields Medalists, three Nobel Laureates, and two Turing Award winners, including Shing-Tung Yau and Andrew Chi-Chih Yao, alongside more than 80 academicians and nearly 1,000 researchers from leading global institutions. President of Tsinghua University Li Luming warmly welcomed scientists from around the world. He emphasized that the ICBS has evolved into a premier platform for global scientists to engage in dialogue and deepen collaboration. Tsinghua University will continue to support Professor Shing-Tung Yau's efforts to advance basic science, and will work together with scientists from all countries to strengthen fundamental research, drive scientific and technological innovation, promote socio-economic development, and jointly create a better future for humanity. Shing-Tung Yau — ICBS President, Fields Medalist, and Chair Professor at Tsinghua University — highlighted recent breakthroughs in mathematics, physics, and information science. He believes a new era driven by theoretical breakthroughs and technological innovations may be dawning. Six trailblazing scientists—Samuel C.C. Ting, Steven Chu, David Gross, Robert Tarjan, Shigefumi Mori, and George Lusztig—were honored with the 2025 Basic Science Lifetime Award, the most prestigious award honoring scientists' contributions to fundamental science. The Congress also awarded 118 Frontiers of Science Awards (FSA) across mathematics, physics, and information science, with winners from over 20 countries. Global AI leaders OpenAI and Meta's FAIR team were also among the recipients. The ICBS was initiated by Shing-Tung Yau in 2023 and is held annually with the theme "Advancing Science for Humanity". Over the next two weeks, nearly 1,000 scholars and students—including over 400 world-leading scientists—will gather at the Beijing Institute of Mathematical Sciences and Applications. Over 500 sessions will cover mathematics, physics, and information science and engineering, with a focus on cutting-edge AI research, interdisciplinary innovation, and frontier theoretical breakthroughs. Beyond academic exchange, ICBS emphasized youth engagement through a diverse range of activities, including the "Tsinghua Day" special event on July 19th. ICBS 2025 celebrates international collaboration and academic exchange in global scientific advancement. "Science thrives on collaboration," said Yau. "This is where the next era of discovery begins."
Cision Canada
14 hours ago
- Cision Canada
Government of Canada improves access to health services for Francophone minority communities Français
MONCTON, NB, July 22, 2025 /CNW/ - Today, the Honourable Marjorie Michel, Minister of Health, accompanied by the Honourable Ginette Petitpas Taylor, Member of Parliament for Moncton—Dieppe, announced more than $78 million in funding over five years to seven organizations including five Atlantic post-secondary training institutions to improve access to health services in French for Francophone communities. These investments will support innovative projects to improve health services in French through the Official Languages Health Program (OLHP). Initiatives include increasing access to care, improving recruitment, internship and placement opportunities in Francophone communities as well as training in francophone post-secondary health programs. The Government of Canda will continue working with partners to improve access to health care services for everyone, including services in the official language of their choice. Quotes "Everyone in Canada should have access to health services in their official language of choice, regardless of where they live. When it comes to health care, a language barrier can lead to a life-or-death situation. This is why the Government of Canada is supporting projects that will improve access to health services for Francophones and Anglophones living in minority communities in Canada." The Honourable Marjorie Michel Minister of Health "As a proud Atlantic Canadian, I know how vital it is for Francophones in minority communities to access health care in their language of choice. This funding will contribute to improved access to more inclusive and effective care — ensuring official languages are supported within our health care system." The Honourable Ginette Petitpas Taylor Member of Parliament for Moncton—Dieppe "Our two official languages are at the heart of our identity, uniting us from coast to coast to coast and making us stronger together. As a government, we are taking concrete action to ensure that Canadians—no matter where they live—can access health services in the official language of their choice. I am pleased that this funding will support projects that strengthen our bilingual identity, not only in the Atlantic region but right across Canada." The Honourable Steven Guilbeault Minister of Canadian Identity and Culture and Minister responsible for Official Languages "Health is essential to the vitality of Francophone and Acadian minority communities, and they should have access to quality health services in their own language. Société Santé en français is proud to work with Canada's 16 French-language health networks and hundreds of other health partners to develop French-language health services across Canada." Antoine Désilets Executive Director, Société Santé en français "The importance of preparing the next generation of French-speaking health care workers, from recruitment to professional integration in Francophone minority communities, cannot be overstated. Health Canada's contribution will leverage the Association des collèges et universités de la francophonie canadienne's (ACUFC) ability to support postsecondary institutions that are members of the Consortium national de formation en santé in their efforts to increase the number of health professionals providing French-language services. It will also allow our network to continue to overcome existing barriers and ensure that Canadians have access to equitable health services in the language of their choice." Martin Normand President and Chief Executive Officer, Association des collèges et universités de la francophonie canadienne - Consortium national de formation en santé "The financial support from the federal government represents much more than a simple investment in health training: it is a concrete gesture in favor of improving access to French-language health services in our Francophone minority communities. At the Université de Moncton, this support will strengthen our capacity to offer training in targeted health programs. We are proud to be part of a national network of 16 post-secondary institutions — a group that fosters collaboration, shares expertise, and promotes our programs. Together, we are helping to train the next generation of competent, committed professionals ready to meet the needs of French-language healthcare across the country." Dr. Denis Prud'homme President and Vice-Chancellor of the Université de Moncton Quick Facts The OLHP was launched in 2003 and receives funding through the Government of Canada's Action Plan for Official Languages. The Program supports non-profit organizations, post-secondary institutions and provincial and territorial governments that aim to improve access to health services for official language minority communities (OLMC) - Francophones living outside Quebec and English-speaking communities in Quebec. The " Action Plan for Official Languages 2023–2028: Protection-Promotion-Collaboration" announced that, in addition to existing funding of $192.2 million over five years, Health Canada's OLHP will also receive $14.5 million over five years (for a total of $206.7 million over five years). This additional funding will support non-profit organizations, provincial and territorial governments and post-secondary institutions that serve OLMCs to train and retain bilingual health professionals, support health networking initiatives as well as innovative projects. Budget 2023 outlined the Government's plan to invest close to $200 billion over 10 years, including $46.2 billion in new funding to provinces and territories to strengthen Canada's public health care system. This includes $25 billion of funding through tailored bilateral agreements to meet the specific needs of each province and territory. Associated Links SOURCE Health Canada (HC)
